77 Results

Phase III REACH-2 study of Cyramza to treat AFP-High liver cancer is published in The Lancet Oncology. - Eli Lilly

 Added 4 days ago

Eli Lilly and Company announced that results from the global Phase III REACH-2 study of Cyramza (ramucirumab) as a single...

FDA approves Cabometyx for hepatocellular carcinoma in patients previously treated with sorafenib.-Exelixis + Ipsen

 Added 6 days ago

Exelixis, Inc. announced that the FDA approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously...

NICE recommends use of Lenvima in liver cancer.- Eisai and Merck Inc.

 Added 1 month ago

The National Institute for Health and Care excellence (NICE) has recommended Lenvima (lenvatinib), from Eisai and Merck Inc., as a...

NICE reverses earlier ruling and recommends use of Stivarga in liver cancer.- Bayer HealthCare.

 Added 1 month ago

The National Institute for Health and Care Excellence (NICE) has recommended the NHS use of Stivarga (regorafenib) from Bayer HealthCare,...

EU approves Cabometyx for liver cancer.- Ipsen + Exelixis.

 Added 2 months ago

Exelixis announced that its partner Ipsen received approval from the European Commission (EC) for Cabometyx (cabozantinib) tablets as a monotherapy...

TAPPAS phase III trial shows ApoStream effective in capturing tumour cells in angiosarcoma.- Precision for Medicine.

 Added 2 months ago

Precision for Medicine and TRACON Pharmaceuticals announced the publication of biomarker results from the TAPPAS phase III clinical trial that...

FDA gives accelerated approval to Keytruda for previously treated hepatocellular carcinoma.- Merck Inc.

 Added 2 months ago

Merck Inc announced that the FDA has approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with hepatocellular...

Lenvima approved in China for liver cancer.- Eisai/Merck Inc.

 Added 4 months ago

Eisai Co and Merck Inc announced today that the China National Medical Products Administration (NMPA) approved the kinase inhibitor Lenvima...

European Commission approves Lenvima to treat hepatocellular carcinoma (liver cancer)- Eisai + Merck Inc.

 Added 4 months ago

Eisai Co., Ltd.and Merck & Co., Inc.,announced that the European Commission (EC) has granted a marketing authorization for the oral...

FDA approves Lenvima for unresectable hepatocellular carcinoma.- Eisai and Merck Inc.

 Added 5 months ago

Eisai Inc. and Merck Inc announced that the FDA has approved Lenvima (lenvatinib) for the first-line treatment of patients with...

Load more